What has NICE said?

What has NICE said?

Lenalidomide (also known as Revlimid) is recommended. This drug is a possible treatment for people with transfusion-dependent anaemia, caused by low- or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality, when other treatments haven't worked well enough.

What does this mean for me?

If you have transfusion-dependent anaemia, caused by low- or intermediate-1 risk myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality and your doctor thinks that lenalidomide is the right treatment, you should be able to have the treatment on the NHS.

Lenalidomide should be available on the NHS within 3 months of the guidance being issued.

  • Information Standard